secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2023-02-13T23:59:59+00:00
Accession:  0001104659-23-018997
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Therapeutics completes 1-for-20 reverse stock split to regain Nasdaq compliance
--------------------------------------------------------------------------------

- Reverse stock split effective 5:00 pm ET on Feb 10, 2023; stock trades split-adjusted from Feb 13, 2023 under symbol APRE.
- Outstanding shares reduced from ~53,631,405 to ~2,681,570; authorized shares and par value unchanged.
- New CUSIP number 03836J201; fractional shares aggregated and sold, with cash payments to holders.
- Split intended to increase per-share price to meet Nasdaq continued listing requirements.
- Proportionate adjustments made to equity awards, option exercise prices, and shares available under plans.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000110465923018997/0001104659-23-018997-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000110465923018997/tm236225d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-018997

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer